First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). To date, no randomized trial has compared VMP to Rd, and there is no evidence of the optimal treatment f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Haematologica
Autori principali: Larocca, Alessandra, Mina, Roberto, Offidani, Massimo, Liberati, Anna Marina, Ledda, Antonio, Patriarca, Francesca, Evangelista, Andrea, Spada, Stefano, Benevolo, Giulia, Oddolo, Daniela, Innao, Vanessa, Cangiolosi, Clotilde, Bernardini, Annalisa, Musto, Pellegrino, Amico, Valeria, Fraticelli, Vincenzo, Paris, Laura, Giuliani, Nicola, Falcone, Antonietta Pia, Zambello, Renato, De Paoli, Lorenzo, Romano, Alessandra, Palumbo, Antonio, Montefusco, Vittorio, Hájek, Roman, Boccadoro, Mario, Bringhen, Sara
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ferrata Storti Foundation 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109734/
https://ncbi.nlm.nih.gov/pubmed/31248973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.220657
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi